Zurich Insurance Group Ltd FI Buys Shares of 45,692 Becton Dickinson and Co (NYSE:BDX)

Zurich Insurance Group Ltd FI bought a new stake in shares of Becton Dickinson and Co (NYSE:BDX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 45,692 shares of the medical instruments supplier’s stock, valued at approximately $11,515,000.

Several other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Becton Dickinson and by 2.3% during the second quarter. Vanguard Group Inc. now owns 23,018,011 shares of the medical instruments supplier’s stock valued at $5,800,769,000 after acquiring an additional 520,350 shares during the last quarter. FMR LLC increased its holdings in shares of Becton Dickinson and by 5.0% in the first quarter. FMR LLC now owns 17,835,000 shares of the medical instruments supplier’s stock valued at $4,453,934,000 after purchasing an additional 842,590 shares during the last quarter. Morgan Stanley increased its holdings in shares of Becton Dickinson and by 66.7% in the second quarter. Morgan Stanley now owns 4,887,187 shares of the medical instruments supplier’s stock valued at $1,231,621,000 after purchasing an additional 1,955,095 shares during the last quarter. Fundsmith LLP increased its holdings in shares of Becton Dickinson and by 0.9% in the first quarter. Fundsmith LLP now owns 3,771,159 shares of the medical instruments supplier’s stock valued at $941,772,000 after purchasing an additional 35,453 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Becton Dickinson and by 1.5% in the second quarter. Northern Trust Corp now owns 3,271,013 shares of the medical instruments supplier’s stock valued at $824,327,000 after purchasing an additional 47,202 shares during the last quarter. 84.21% of the stock is owned by institutional investors and hedge funds.

In other news, Director Claire Fraser sold 1,429 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $243.26, for a total transaction of $347,618.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Vincent A. Forlenza sold 11,532 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $260.38, for a total value of $3,002,702.16. Following the transaction, the chief executive officer now owns 218,671 shares of the company’s stock, valued at $56,937,554.98. The disclosure for this sale can be found here. Insiders sold 37,249 shares of company stock valued at $9,616,803 over the last quarter. 0.12% of the stock is currently owned by company insiders.

BDX has been the subject of several recent research reports. Raymond James increased their price target on Becton Dickinson and from $265.00 to $288.00 and gave the company a “strong-buy” rating in a report on Friday, June 28th. Wells Fargo & Co increased their price target on Becton Dickinson and from $270.00 to $290.00 and gave the company an “outperform” rating in a report on Friday, September 6th. Morgan Stanley increased their price target on Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a report on Tuesday, July 16th. ValuEngine cut Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Piper Jaffray Companies cut their price target on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Five research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $266.55.

Becton Dickinson and stock traded down $2.83 during mid-day trading on Friday, hitting $253.55. The company’s stock had a trading volume of 1,448,134 shares, compared to its average volume of 902,623. The firm has a market capitalization of $69.52 billion, a PE ratio of 23.03, a price-to-earnings-growth ratio of 1.82 and a beta of 1.13. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $265.87. The company has a current ratio of 1.09, a quick ratio of 0.67 and a debt-to-equity ratio of 0.84. The stock’s fifty day moving average is $252.96 and its two-hundred day moving average is $245.64.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, topping the consensus estimate of $3.05 by $0.03. The company had revenue of $4.35 billion during the quarter, compared to analyst estimates of $4.37 billion. Becton Dickinson and had a return on equity of 14.78% and a net margin of 5.02%. The firm’s revenue for the quarter was up 1.7% compared to the same quarter last year. During the same period in the prior year, the business posted $2.91 earnings per share. On average, equities analysts expect that Becton Dickinson and Co will post 11.68 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be given a $0.77 dividend. The ex-dividend date of this dividend is Friday, September 6th. This represents a $3.08 annualized dividend and a yield of 1.21%. Becton Dickinson and’s payout ratio is 27.97%.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: Net Income

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit